438 related articles for article (PubMed ID: 12139895)
21. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
[TBL] [Abstract][Full Text] [Related]
22. Screening for cystic fibrosis: the importance of using the correct tools.
Shah U; Moatter T
J Ayub Med Coll Abbottabad; 2006; 18(1):7-10. PubMed ID: 16773960
[TBL] [Abstract][Full Text] [Related]
23. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
[TBL] [Abstract][Full Text] [Related]
24. Thirty-years of screening for cystic fibrosis in East Anglia.
Calvin J; Hogg SL; McShane D; McAuley SA; Iles R; Ross-Russell R; MacLean FM; Heeley ME; Heeley AF;
Arch Dis Child; 2012 Dec; 97(12):1043-7. PubMed ID: 23076339
[TBL] [Abstract][Full Text] [Related]
25. Retrospective analysis of stored dried blood spots from children with cystic fibrosis and matched controls to assess the performance of a proposed newborn screening protocol in Switzerland.
Barben J; Gallati S; Fingerhut R; Schoeni MH; Baumgartner MR; Torresani T;
J Cyst Fibros; 2012 Jul; 11(4):332-6. PubMed ID: 22300503
[TBL] [Abstract][Full Text] [Related]
26. Immunoreactive trypsin/DNA newborn screening for cystic fibrosis: should the R117H variant be included in CFTR mutation panels?
Scotet V; Audrézet MP; Roussey M; Rault G; Dirou-Prigent A; Journel H; Moisan-Petit V; Storni V; Férec C
Pediatrics; 2006 Nov; 118(5):e1523-9. PubMed ID: 17015492
[TBL] [Abstract][Full Text] [Related]
27. High heterogeneity of CFTR mutations and unexpected low incidence of cystic fibrosis in the Mediterranean France.
des Georges M; Guittard C; Altiéri JP; Templin C; Sarles J; Sarda P; Claustres M
J Cyst Fibros; 2004 Dec; 3(4):265-72. PubMed ID: 15698946
[TBL] [Abstract][Full Text] [Related]
28. Novel strategies in newborn screening for cystic fibrosis: a prospective controlled study.
Vernooij-van Langen AM; Loeber JG; Elvers B; Triepels RH; Gille JJ; Van der Ploeg CP; Reijntjens S; Dompeling E; Dankert-Roelse JE;
Thorax; 2012 Apr; 67(4):289-95. PubMed ID: 22271776
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations.
Hammond KB; Abman SH; Sokol RJ; Accurso FJ
N Engl J Med; 1991 Sep; 325(11):769-74. PubMed ID: 1870650
[TBL] [Abstract][Full Text] [Related]
30. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
[TBL] [Abstract][Full Text] [Related]
31. Lessons learned from 20 years of newborn screening for cystic fibrosis.
Massie RJ; Curnow L; Glazner J; Armstrong DS; Francis I
Med J Aust; 2012 Jan; 196(1):67-70. PubMed ID: 22256939
[TBL] [Abstract][Full Text] [Related]
32. Newborn screening for cystic fibrosis in Switzerland--consequences after analysis of a 4 months pilot study.
Torresani T; Fingerhut R; Rueegg CS; Gallati S; Kuehni CE; Baumgartner MR; Barben J;
J Cyst Fibros; 2013 Dec; 12(6):667-74. PubMed ID: 23712087
[TBL] [Abstract][Full Text] [Related]
33. Neonatal screening for cystic fibrosis: comparing the performances of IRT/DNA and IRT/PAP.
Sarles J; Giorgi R; Berthézène P; Munck A; Cheillan D; Dagorn JC; Roussey M
J Cyst Fibros; 2014 Jul; 13(4):384-90. PubMed ID: 24513262
[TBL] [Abstract][Full Text] [Related]
34. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
[TBL] [Abstract][Full Text] [Related]
35. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
[TBL] [Abstract][Full Text] [Related]
36. Newborn screening for cystic fibrosis in Serbia: a pilot study.
Radivojevic D; Sovtic A; Minic P; Grkovic S; Guc-Scekic M; Lalic T; Miskovic M
Pediatr Int; 2013 Apr; 55(2):181-4. PubMed ID: 23163630
[TBL] [Abstract][Full Text] [Related]
37. Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers.
Castellani C; Picci L; Scarpa M; Dechecchi MC; Zanolla L; Assael BM; Zacchello F
Am J Med Genet A; 2005 Jun; 135(2):142-4. PubMed ID: 15832355
[TBL] [Abstract][Full Text] [Related]
38. Borderline sweat test: Utility and limits of genetic analysis for the diagnosis of cystic fibrosis.
Seia M; Costantino L; Paracchini V; Porcaro L; Capasso P; Coviello D; Corbetta C; Torresani E; Magazzù D; Consalvo V; Monti A; Costantini D; Colombo C
Clin Biochem; 2009 May; 42(7-8):611-6. PubMed ID: 19318035
[TBL] [Abstract][Full Text] [Related]
39. [Genotype and phenotype of gastrointestinal symptoms analysis in children with cystic fibrosis].
Iwańczak F; Smigiel R; Stawarski A; Pawłowicz J; Stembalska A; Mowszet K; Sasiadek M
Pol Merkur Lekarski; 2005 Feb; 18(104):205-9. PubMed ID: 17877132
[TBL] [Abstract][Full Text] [Related]
40. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
